Tirzepatide linked to less CPAP use and lower mortality in sleep apnea study

A large study published online December 22, 2025 in a JAMA journal found that adults with type 2 diabetes, obesity and obstructive sleep apnea who started an incretin receptor agonist were less likely to use a CPAP machine, be hospitalized or die during follow-up than similar patients who started an SGLT2 inhibitor ^[1].

The analysis used de-identified electronic health record data from the TriNetX research network and was designed as a target trial emulation. It included 36,981 patients with a mean age of 62.3 years (standard deviation 11.3). Patients were matched 1-to-1 on propensity scores to balance their baseline characteristics, and the results were analyzed with Cox proportional hazard models ^[1].

Compared with SGLT2 inhibitor use, starting an incretin receptor agonist was associated with lower rates of CPAP use (hazard ratio 0.92; 95% CI, 0.87-0.97), all-cause mortality (hazard ratio 0.68; 95% CI, 0.60-0.77) and hospitalization (hazard ratio 0.90; 95% CI, 0.86-0.95) ^[1]. A hazard ratio below 1.0 means the event happened at a lower rate in that group during the study period; the study does not report how many patients in each group had each outcome, how long they were followed, or what doses they took ^[1].

Both tirzepatide and GLP-1 receptor agonists were associated with reduced risks for CPAP use and mortality compared with SGLT2 inhibitors, with larger reductions seen with tirzepatide. Subgroup analyses were generally consistent, but no link between the drugs and CPAP use was seen among women or older adults ^[1].

The study population was 70.5% White, 18.6% Black, 2.1% Asian, 6.7% Hispanic and 0.7% Native Hawaiian or Other Pacific Islander. The authors noted that obstructive sleep apnea affects roughly 25% of US adults and often occurs alongside type 2 diabetes because of shared risk factors such as obesity, and that CPAP adherence remains low ^[1].

The researchers listed limitations: CPAP use was identified through procedure codes, which may not accurately capture real-world use, adherence or disease severity, and unmeasured factors such as socioeconomic status and the severity of sleep apnea could have influenced the results ^[1]. Because this is an observational cohort rather than a randomized trial, it can show associations but cannot prove that the drugs caused the differences ^[1].

Why it matters for patients

Sleep apnea and type 2 diabetes frequently overlap, and for many people CPAP therapy is hard to stick with ^[1]. This analysis adds real-world data from routine care to earlier research that had shown incretin drugs, tirzepatide in particular, may improve sleep apnea severity ^[1].

What it does not do is settle the question. The findings are described as associations, not proof of cause and effect, and the study reports no absolute numbers, no dosing information and no follow-up length ^[1]. It also included only people who had all three conditions — type 2 diabetes, obesity and obstructive sleep apnea — so it does not show whether the results would look the same in adults taking these drugs for weight loss alone, or in people without diabetes ^[1]. Nothing in the study addresses insurance coverage, prescribing rules or whether patients already using CPAP fared differently from those who were not.

What happens next

Whether the findings lead to labeling changes, coverage decisions or new randomized trials has not been reported ^[1].